Alkermes Inc. plc (ALKS) is a publicly traded Healthcare sector company. As of May 21, 2026, ALKS trades at $38.05 with a market cap of $6.20B and a P/E ratio of 40.06. ALKS moved -0.08% today. Year to date, ALKS is +32.07%; over the trailing twelve months it is +16.77%. Its 52-week range spans $25.17 to $39.56. Analyst consensus is strong buy with an average price target of $45.75. Rallies surfaces ALKS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alkermes jumps after positive Phase 3 REVITALYZ topline results for LUMRYZ in IH: Alkermes announced positive topline Phase 3 results from the REVITALYZ study evaluating investigational use of LUMRYZ in adults with idiopathic hypersomnia. The update was released on May 12, 2026 and provides a clear same-day catalyst for ALKS shares.
| Metric | Value |
|---|---|
| Price | $38.05 |
| Market Cap | $6.20B |
| P/E Ratio | 40.06 |
| EPS | $0.93 |
| Dividend Yield | 0.00% |
| 52-Week High | $39.56 |
| 52-Week Low | $25.17 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.56B |
| Net Income | $152.72M |
| Gross Margin | 86.63% |
15 analysts cover ALKS: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.75.